Expertise in
3
conditions

Wenxiu J. Yao

Chengdu, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
3
conditions
Chengdu, CN 

Overview

Wenxiu Yao practices practicing medicine in Chengdu, China.

Yao is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Squamous Cell Lung Carcinoma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and EGFR Positive Lung Cancer.

They are actively involved in clinical research, co-authoring 53 peer reviewed articles and participating in 2 clinical trials.

Locations

Chengdu, China
Other Locations
China
Xinxiang, China
Chengjiao, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: April 03, 2026
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
Enrollment Status: Completed
Publish Date: December 19, 2025
Intervention Type: Drug
Study Drugs: Pyrotinib, Docetaxel
Study Phase: Phase 3
View 1 Less Clinical Trial

53 Total Publications

Plain language summary: comparing ivonescimab with pembrolizumab in people with PD-L1-positive non-small cell lung cancer in the HARMONi-2 study.
Plain language summary: comparing ivonescimab with pembrolizumab in people with PD-L1-positive non-small cell lung cancer in the HARMONi-2 study.
Journal: Future oncology (London, England)
Published: December 29, 2025

Frequently Asked Questions about Wenxiu J. Yao

Is Wenxiu J. Yao a top-rated expert for Squamous Cell Lung Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Wenxiu J. Yao is classified as an Advanced expert for Squamous Cell Lung Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Wenxiu J. Yao participate in research or clinical trials?

Yes. Wenxiu J. Yao has published 53 articles and abstracts on conditions like Squamous Cell Lung Carcinoma. You can view a list of Wenxiu J. Yao's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yao's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile